Volume 26, Issue 2 (3-2022)                   ibj 2022, 26(2): 110-115 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Aghabozorg Afjeh S S, Shams J, Hamednia S, Boshehri B, Amini A, Omrani A et al . Validating MARK2 Gene Polymorphism as a Predictor of Response to Lithium Treatment in Bipolar Patients. ibj. 2022; 26 (2) :110-115
URL: http://ibj.pasteur.ac.ir/article-1-3629-en.html
Background: Lithium is a therapeutic option for the treatment of the acute phase of the bipolar disorder and long-term management of this disorder. However,  it  is  estimated  that  10  to  60%  of  patients  do  not  properly response to this medication.
Methods: To investigate the role of MARK2 gene in response to lithium, we genotyped the MARK2 rs10792421 polymorphism in Iranian bipolar patients using ARMS-PCR.
Results: Results of this study showed a significant association of this polymorphism with response to lithium. The A allele was more frequent in the  responder  than  the  non-responder  group  and  also  in  the  semi- responder group compared to the non-responder group in the codominant model of analysis. AA and AG genotypes were more frequent in both the responder and semi-responder groups compared to the non-responder group in dominant model of analysis.
Conclusion: Based on the findings of the current study, the rs10792421 variant of MARK2 gene could be considered as a potential biomarker for predicting the treatment outcome of bipolar disorder type 1 in Iranian population.
Type of Study: Full Length | Subject: Related Fields

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Iranian Biomedical Journal

Designed & Developed by : Yektaweb